{"name":"Tillotts Pharma AG","slug":"tillotts-pharma-ag","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Mesalamin","genericName":"Mesalamin","slug":"mesalamin","indication":"Other","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"TP05","genericName":"TP05","slug":"tp05","indication":"Atopic dermatitis","status":"phase_3"}]}],"pipeline":[{"name":"Mesalamin","genericName":"Mesalamin","slug":"mesalamin","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TP05","genericName":"TP05","slug":"tp05","phase":"phase_3","mechanism":"TP05 is a topical phosphodiesterase 4 (PD4) inhibitor that reduces inflammatory cytokine production in skin.","indications":["Atopic dermatitis","Psoriasis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE5BZGVEa0cwYlJPV2ZfdzNMQjFTZW1aRGlWdGxhZGUzTmNoR2V1MzNCWDZLTnFwcGdXVHFtaGdiVE42dWQ4aEQ0eGlJeGVIVUR3QU1WUFh2XzRvZnBWU3F1c1pla0U4Z2dERC1ib1V0TQ?oc=5","date":"2024-12-11","type":"pipeline","source":"The Times","summary":"Innovation takes centre stage at Pharma Industry Awards UK 2024 - The Times","headline":"Innovation takes centre stage at Pharma Industry Awards UK 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxQR21abEVhQXhnVmtRc1plLUtDa3IxQVUyUk5ZR1Q3SnU1Q0FpenJJOGRHdjJnMUQxSTRBXzZnU0pMbmxHZGhtR1ljNjM2a1pmT1hTTVF3bDN1c1VUb1EtT2ZZUDFzQmMyZ0dqUFgxS1ViR0M4ejJCT1hOZlRDWHRwVDdvX3hQclBzM0dIZHFQMFE1SkY0cHhRRmt0R3lJSFAtM0N5R05vcXNWZGtSTnc5V0NwZHNNeFJVMXZES29CX3o4d190SVVQXzd1VVczYjhaaW1QQWZFVQ?oc=5","date":"2023-07-21","type":"pipeline","source":"BioWorld News","summary":"Mage Biologics receives investment to develop oral monoclonal antibody targeting ulcerative colitis - BioWorld News","headline":"Mage Biologics receives investment to develop oral monoclonal antibody targeting ulcerative colitis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxNd2x0VWstOWhIYWQ5RHpINEswVGRka3RZVEtSZnBSZFg2YTJSaF91QUdka1Zna3J1TjRhX2pqSHZRMkhMUzlWREtMZWpUbWpST2w1R2NiWTR2bXFHbHc1RThLQ2d1dW8tcFBQVGlmRjhDdWVOX3VSV3RzbkZIUDViR0FuMnZ4Njg3R2wyQ0JoUW95QTNYNjBNYWFVSENoajJwTWI0bVV5T2xQQjhlZ3I1bldoeW9BTnM5eWFGOEpRVmlCdHd6MWsyRm5WbFRTVmFQWlJ2QUV3V0dBYTBBbWU1ZmJWUnlVZ24zdjcxX3hyaw?oc=5","date":"2023-05-30","type":"pipeline","source":"European Medical Journal","summary":"Clostridioides difficile Infection: Targeting an Unwelcome and Persistent Threat - European Medical Journal","headline":"Clostridioides difficile Infection: Targeting an Unwelcome and Persistent Threat","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQN1QzTjRnN0dvYzlxYWhOMHp1cFc2NGlUVEJtdnFEUlBkYl93aGt5d080OHRtT0FfSnYzTUVyTk1LZ0ljLTgyS2x5X2hWck9oQ2xRZ0NLVUNidEpOMWVsRUI3RGpQQ0FLX3J4SG5PVXpKeFlDandRSUNDMXJFdE1hUnlwTkRqc0VnNnl5My1qU1FhZG1wNTlRTzdlT0E4MHBTME84ekRlM3Biam9sVXhSc040SW0wRmNQNG1R?oc=5","date":"2023-04-07","type":"pipeline","source":"BioPharma APAC","summary":"Tillotts Pharma AG announces the launch of Octasa® 1600 mg tablets in Canada - BioPharma APAC","headline":"Tillotts Pharma AG announces the launch of Octasa® 1600 mg tablets in Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOOURTZWphbFBxYnhld1ZudjUwVF9NY0RKM001SHNRd0YwclpUTEVXa1NWbWVnQWUxM3BYOHM2anNUZXkxN29pXzJqQVJ1LTVCeTJmQmhaSU5WOUM4V2l3aEhJWFNFdFRya2U1Ty1BRWNmSDVBQ2Zfb182TTM3Tl9neWo1Z1ZIYWNXTVVaRU5QYVJmcWh5LVJac1NnNHNJMlJvMmh2THVDVDk?oc=5","date":"2022-10-25","type":"pipeline","source":"Labiotech.eu","summary":"Delayed release tablets to treat ulcerative colitis launched in Canada - Labiotech.eu","headline":"Delayed release tablets to treat ulcerative colitis launched in Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxPVFRST0hqSXp1cXA1NFZLeHpnd1M4RWtHVE5xSTkxdTdSU2lYcnN1TmJVN1MtWGp0QndsOTRiR0k0aHV6M3RVbHJiUGpJMFJpb21JTmpOcnV5dlBnSUxQaTVzaTNLN2NDN0t1ZjhvRUUtd1BJNFR2Y2VzYUJ5ZVVCLUtxMDJIVnA2S2RKa1hVb1BKZkx4aV9pV2RSSkd5Vk84bjU2MmRrUzZuSzh3RGhleHJtYjFBWHlTUmhSVUtmcUpRaDN1Z3gxRXFEV1FLY1U?oc=5","date":"2022-09-28","type":"pipeline","source":"Veeva","summary":"Tillotts Standardizes on Veeva Commercial Cloud Applications to Power Digital Engagement in Europe - Veeva","headline":"Tillotts Standardizes on Veeva Commercial Cloud Applications to Power Digital Engagement in Europe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxPN1RrLTVDcXY5NHF1aWs4ZUJHZjUxcHRPZ3BxQ1llclFLT0hPNWpxeEd1OC1VOE5TTnZIZ3BDemhSOUdfeGtPXzhXaE1wSXRTcHRzNEI5VVdtODBFdEk1em5meXRnNGE4Q2pUWkRMN1A3RU1DeUFxT2l2OF9TWUFVZzJhdnZ4NkhOOXpHOHpOZk51emV3WTRMVEdvRk9kNi12N0s4UGtuTVJvTmlEZmJBNkdKSjdwYjFLaFFFMW02c0JqVmRWYUxmZk5wUUpCclhnaGZ3aGoyR0t2OEZlVHVXcGpCQW5CQUxfcldncE50R245TjZ2azhqcGNHSmpCeVk4am9TdTA1Q3FHUXVGRElLdWFTamEzNHk4cURReElZdXhaQ1ha?oc=5","date":"2021-12-07","type":"pipeline","source":"Business Wire","summary":"(fidaxomicin) is recommended for the treatment of Clostridioides difficile infection (CDI) by ESCMID - Business Wire","headline":"(fidaxomicin) is recommended for the treatment of Clostridioides difficile infection (CDI) by ESCMID","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQZEx1WFFSN3pfSERYbVFuZGZ3MVlySEtTLXljSER5RXItUUdIVjIxU0xBdlA4N3VHaU5iWHdYenRWMTE2bHlCMEhwWllncUpGS2ZfSFFxdU9JLV84RnhHSlBGSVVRejBUYk16NFZ1S1lhbEEzcG5YWmVwZjY5a1JEX2FyekxRSkx4bmYyZjg0d0pWTS1oMDJ3ZjJJMTVDank1RF95aDN2ZGRUei1fYW5ZQm1vQlc0dDdwSG12V014VnZ6UQ?oc=5","date":"2021-07-29","type":"pipeline","source":"BioSpectrum Asia","summary":"Switzerland's Tillotts Pharma AG launches ulcerative colitis drug in China - BioSpectrum Asia","headline":"Switzerland's Tillotts Pharma AG launches ulcerative colitis drug in China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQc25WV0VOalJ2Tm00XzNvSUllNkNBUTliQXhWbXpWYVJYREU3YjI5aHBJSG1vS25ZLVJiR3lVRjN4a2FUZTgxR0pOTW5ZU0MtZTJyNjVJRGRCcE9NdU4wVEQ3cWVmaHFoZmJOdmhhS0wtaDVrbzhRY3RjQlNNMjhIdlZGaHpPby1wQ01oclJacXNLRk40aXJZNnhDekE3SlJpY3h0WjBFUWNueWQ5aUhhdHBfUW1sYW9hMWVTR3FxOA?oc=5","date":"2017-02-23","type":"pipeline","source":"PR Newswire","summary":"Tillotts Pharma in Germany Dedicated to Gastrointestinal Health - PR Newswire","headline":"Tillotts Pharma in Germany Dedicated to Gastrointestinal Health","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxONFQxenU1REJ6WW9RYkZoa2FFRS1uWWo4SHFaNU5xX3ZFVVdpeEY2dE9SUFVQb2VOQmZ6VWpPM3FOZ3g0dFRfUWxnUjVTX1E2cHRMaXlpb1FxWk11QmU3T0hhNzZFYXhObHF1d2pjZFc5ZFlJcG1HLVlKT2lhN083alNVcWg5TlpNWmZ2VzNobHgyWVFwY1BJOFhtbTNDVEl2ZnY4MDdoSWtYUnhQMDcybjhlLUxmUEF5RzhJMHB5aFU2UWs4cGkyeUlWTTlYR2o3NENn?oc=5","date":"2015-07-17","type":"pipeline","source":"AstraZeneca","summary":"AstraZeneca completes agreement with Tillotts Pharma for Entocort - AstraZeneca","headline":"AstraZeneca completes agreement with Tillotts Pharma for Entocort","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOaGNJbjhNdUFDTEEzdUZ6Q19YNUx0c1d3RThua3ByTU0zWUs2Z1BIR0RXc3NQaUlZWV92X3ItWkQ0UDBYNWR5ZktXR1JxOGNVdG1FMWoteVp2bW01UEtNYVY5N09oLTZaOW5TcVF6SmpOVjhTallWNTMzM3U4eXo4ZlBQa1JKOVcxQ0ZXSWg1LU42SmZFZFJRUnFuU0pHNkVtaUFGcnh2enFsOEJma1VqdzFBdkUwM0hwekx6WjNBOWo3aG5WTXNF?oc=5","date":"2015-07-09","type":"pipeline","source":"AstraZeneca","summary":"AstraZeneca sharpens focus on main therapy areas through agreement with gastroenterology specialist Tillotts Pharma for Entocort - AstraZeneca","headline":"AstraZeneca sharpens focus on main therapy areas through agreement with gastroenterology specialist Tillotts Pharma for ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxNZms2R0lyOC1ZMU1mU3MzSXRiNmVKZkduMmNRNHJETWN4VWkyN2ZWVDhPeFduNHBzZnYtQkItMDNhaGZpaENnQ1hTT0R5M3pvcWJYbmk1WkFwdjduck5LNl9IVVBJQmhpZ2lZZVVVWVBHend0a3h2MXc1ZTV1cFZ1dGp4LUpENHM4eTBzelNMSXd3VG5hd29CTUpxOXZwdlU1ODEzcUlUWDk0Y1RQbjIxbzlzMGtJVVowYlEtWTZxWWpkLXc0R3B6WHZvQkFGNUVUMXV4cmozT20xU3NBU0ZSY3dGdEtWNnJydFZJ?oc=5","date":"2015-03-17","type":"pipeline","source":"News-Medical","summary":"Improving adherence to ulcerative colitis medications: an interview with Mattias Norrman, COO, Tillotts Pharma - News-Medical","headline":"Improving adherence to ulcerative colitis medications: an interview with Mattias Norrman, COO, Tillotts Pharma - News","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":1,"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}